Cargando…

Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

Objective. To compare healthcare utilization (HCU) and costs of women newly diagnosed with metastatic breast cancer (mBC) by receipt of HER2-targeted agents (H2T) and among H2T subgroups. Methods. Adult women newly diagnosed with mBC (index date) during 2008–2012 were followed until enrollment end o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer, Nicole, Hao, Yanni, Song, Xue, Shi, Nianwen, Johnson, William, Willemann Rogerio, Jaqueline, Yardley, Denise A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142303/ https://www.ncbi.nlm.nih.gov/pubmed/25180099 http://dx.doi.org/10.1155/2014/475171

Ejemplares similares

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Taxanes in the elderly patient with metastatic breast cancer
por: Yardley, Denise A
Publicado: (2015)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Temporal trend of population structure, burden of diseases, healthcare resources and expenditure in China, 2000–2019
por: Liang, Zhenguo, et al.
Publicado: (2023)

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

CancerCostMod: a model of the healthcare expenditure, patient resource use, and patient co-payment costs for Australian cancer patients
por: Bates, Nicole, et al.
Publicado: (2018)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Correction to: CancerCostMod: a model of the healthcare expenditure, patient resource use, and patient co-payment costs for Australian cancer patients
por: Bates, Nicole, et al.
Publicado: (2019)

Expenditure and resource utilisation for cervical screening in Australia
por: Lew, Jie-Bin, et al.
Publicado: (2012)

Healthcare use and expenditure for diabetes in Bangladesh
por: Shariful Islam, Sheikh Mohammed, et al.
Publicado: (2017)

Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data
por: Lang, Kathleen, et al.
Publicado: (2014)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

Incremental Healthcare Resource Utilization and Expenditures Associated with Cardiovascular Diseases in Patients with Diabetes: A Cross-Sectional Study
por: Ebrahimoghli, Reza, et al.
Publicado: (2022)

Impact of an intradialysis virtual-reality-based exercise program on healthcare resources expenditure: a micro-costing analysis
por: García-Testal, Alicia, et al.
Publicado: (2022)

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
por: Miller, Kathy, et al.
Publicado: (2016)

Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US
por: Xie, Jipan, et al.
Publicado: (2015)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Decoupling of Elderly Healthcare Demand and Expenditure in China
por: Yang, Shangguang, et al.
Publicado: (2021)

Socioeconomic differences in healthcare expenditure and utilization in The Netherlands
por: Loef, Bette, et al.
Publicado: (2021)

Healthcare cost expenditures associated to frailty and sarcopenia
por: Álvarez-Bustos, Alejandro, et al.
Publicado: (2022)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

Effects of life-sustaining treatment plans on healthcare expenditure and healthcare utilization
por: Jeong, Wonjeong, et al.
Publicado: (2023)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

Semantic Role Labeling
por: Palmer, Martha, et al.
Publicado: (2011)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Association of cardiovascular risk profile with healthcare expenditure and resource utilization in chronic obstructive pulmonary disease, with and without atherosclerotic cardiovascular disease
por: Jafar, Zain, et al.
Publicado: (2020)

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
por: Ulrich, Lara, et al.
Publicado: (2021)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Healthcare resource utilization in patients treated with empagliflozin in East Asia
por: Sheu, Wayne H‐H, et al.
Publicado: (2022)

Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy
por: Zheng, Ying, et al.
Publicado: (2021)

The impact of age and sex on healthcare expenditure of households in Bangladesh
por: Sarker, Abdur Razzaque, et al.
Publicado: (2014)

Assessing the determinants of healthcare expenditures in single-person households
por: Tur-Sinai, Aviad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pjgh3tcqcvs09d5n6kqe13i49i